Sputnik V generated a robust and durable T-cell response. Credit: Marco Verch Professional Photographer / Flickr.

The Russian Direct Investment Fund (RDIF) has reported that the Covid-19 vaccine Sputnik V and the single-dose Sputnik Light booster vaccine demonstrated effectiveness against the Omicron variant of the SARS-CoV-2 virus in a study.

Carried out by the Gamaleya Center in Russia, the laboratory study found that both the vaccines demonstrated greater virus neutralising activity (VNA) against Omicron and could potentially offer a robust defence against severe Covid-19 and hospital admission.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As against other available vaccines, Sputnik V showed a three to seven times decline in virus neutralising activity against Omicron.

Data showed that Sputnik V provided 11.8 times decline in VNA versus 41 and 49-84 times reduction for Covid-19 vaccines of Pfizer-BioNTech and Moderna, respectively.

Sputnik V induced a robust and durable T-cell response while the mutations in the Omicron variant did not impact 80% of epitopes in the spike protein.

Furthermore, heterologous boosting with Sputnik Light was demonstrated to improve the efficacy of vaccines, even against Omicron and offered extended booster protection duration.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Data showed that Sputnik Light administered as a booster caused a substantial surge in virus neutralising activity against Omicron two to three months after revaccination.

In mix and match trials carried out in Argentina, Sputnik Light when administered in combination with AstraZeneca, Sinopharm, Moderna and Cansino’s vaccines demonstrated to elicit robust antibody and T-cell response versus homologous vaccine regimen.

In addition, each vaccine cocktail provided a greater antibody titer on the 14th day following the second shot versus the vaccination homogenous shots.

A combination of AstraZeneca’s vaccine plus Sputnik Light demonstrated strong neutralising antibodies growth in a trial in the Republic of Azerbaijan, RDIF reported in September this year.

Currently, Sputnik Light is registered in over 20 countries as a standalone vaccine as well as a universal booster to other shots.

Both Sputnik V and Sputnik Light are not linked to rare serious adverse events including myocarditis or pericarditis.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact